ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interleukins (IL)"

  • Abstract Number: 2878 • 2019 ACR/ARP Annual Meeting

    Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis

    Philip Mease1, Saima Chohan 2, Ferran J. García Fructuoso 3, Alice Gottlieb 4, Richard C. Chou 5, Alan Mendelsohn 6, Rocco Ballerini 6 and Michael E. Luggen 7, 1Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, 2Arizona Arthritis and Rheumatology Research, PLLC, Phoenix, AZ, USA, Phoenix, AZ, 3Hospital CIMA Sanitas, Barcelona, Spain, Barcelona, Spain, 4Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York City, NY, 5University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, 6Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, 7Cincinnati Rheumatic Disease Study Group, Inc. and University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cincinnati, OH

    Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved for moderate-to-severe plaque psoriasis treatment and is under investigation for PsA. This study evaluated the…
  • Abstract Number: 950 • 2019 ACR/ARP Annual Meeting

    Low-Dose IL-2 Effectively Restored Decreased Regulatory T Cells in Patients with Behcet’s Disease

    Xiao-qing Liu1, Xiaojie Liu 2, Nalin Lai 3, Ting Cheng 1, Chong Gao 4 and Xiao-feng Li 1, 1The Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), 2Taiyuan University of Technology, Taiyuan, China (People's Republic), 3Shanxi Medical University, Taiyuan, China (People's Republic), 4Brigham and Women’s Hospital, Harvard Medical School, Boston

    Background/Purpose: Behcet’s disease (BD) is a chronic multisystemic disease characterized by muco-cutaneous and ocular manifestations, with central nervous system, vascular and/or gastro-intestinal involvement. Several studies…
  • Abstract Number: 2881 • 2019 ACR/ARP Annual Meeting

    Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study

    Philip Mease1, Laure Gossec 2, Laura Coates 3, Alice B. Gottlieb 4, Deepak Assudani 5, Barbara Ink 5, Jason Coarse 6, Oscar Irvin-Sellers 5 and Dafna Gladman 7, 1Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, 2Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, 3University of Oxford, Oxford, United Kingdom, 4Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, Philadelphia, PA, 5UCB Pharma, Slough, UK, Slough, United Kingdom, 6UCB Pharma, Raleigh, NC, USA, Raleigh, NC, 7Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada

    Background/Purpose: The ultimate goal of therapy in patients with psoriatic arthritis (PsA) is clinical remission, defined as ‘the absence of clinical and laboratory evidence of…
  • Abstract Number: 1504 • 2019 ACR/ARP Annual Meeting

    Subcutaneous Secukinumab 150 Mg Provides Rapid and Sustained Relief in Total and Nocturnal Back Pains, Morning Stiffness, and Fatigue in Patients with Active Ankylosing Spondylitis over 4 Years

    Helena Marzo-Ortega1, Corinne Miceli-Richard 2, Sonja Gill 3, Marina Magrey 4, Paula Machado 5, Abhijit Shete 6, Jianyuan Wang 6, Susanne Rohrer 6 and Atul Deodhar 7, 1NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom, 2Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, 3412 – 3075 Hospital Gate, Oakville, Canada, 4Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, 6Novartis Pharma AG, Basel, Switzerland, 7Oregon Health & Science University, Portland, OR

    Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory condition. Pain, stiffness, and fatigue are reported as the most troubling symptoms by 70–80%, 20–40%, and 50–60%…
  • Abstract Number: 2909 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of the Selective Interleukin-1 Receptor Associated Kinase 4 Inhibitor, PF-06650833, in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

    Spencer I Danto1, Negin Shojaee 1, Ravi Shankar P Singh 1, Zorayr Manukyan 2, Jessica Mancuso 1, Elena Peeva 1, Michael Vincent 1 and Jean Beebe 1, 1Pfizer Worldwide Research & Development, Immunology, and Inflammation Research Unit, Cambridge, MA, 2Pfizer Worldwide Research & Development, Immunology, and Inflammation Research Unit, ..

    Background/Purpose: Adaptive and innate immune pathways are involved in inflammation and pathogenesis of rheumatoid arthritis (RA). Toll-like receptor (TLR) stimulation activates the innate immune system,…
  • Abstract Number: 1517 • 2019 ACR/ARP Annual Meeting

    Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis

    Iain McInnes1, Dafna Gladman 2, Atul Deodhar 3, Corinne Miceli-Richard 4, Peter Nash 5, Naveed Sattar 6, Nehal Mehta 7, Darren Asquith 8, Jianyuan Wang 9, Hanno Richards 9, Luminita Pricop 10 and Abhijit Shete 9, 1Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, 3Oregon Health & Science University, Portland, OR, 4Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, 5University of Queensland, Brisbane, Queensland, Australia, 6Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, 7National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, 8Novartis Pharmaceuticals UK Limited, Surrey, United Kingdom, 9Novartis Pharma AG, Basel, Switzerland, 10Novartis Pharmaceuticals Corporation, East Hanover, NJ

    Background/Purpose: Systemic inflammation may influence cardio-metabolic profiles and increases the risk of CV disorders in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients (pts)1. Treatment…
  • Abstract Number: 1523 • 2019 ACR/ARP Annual Meeting

    Impact of Body Weight on Efficacy of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis

    Alan Menter 1, Zoe Draelos 2, Jayme Heim 3, Jeff Parno 4, Alan Mendelsohn4, Stephen Rozzo 4 and Christopher Griffiths 5, 1Division of Dermatology, Baylor Scott & White, and Texas A&M College of Medicine, Dallas, TX, USA, Dallas, TX, 2Dermatology Consulting Services, High Point, NC, USA, High Point, NC, 3West Michigan Dermatology, Holland, MI, USA, Holland, MI, 4Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, 5Centre for Dermatology Research, The University of Manchester, Manchester, UK, Manchester, United Kingdom

    Background/Purpose: Tildrakizumab (TIL) is a high-affinity, anti–interleukin‐23p19 monoclonal antibody approved for the treatment of moderate-to-severe chronic plaque psoriasis. An inverse efficacy–body weight relationship has been…
  • Abstract Number: L17 • 2018 ACR/ARHP Annual Meeting

    Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study

    Christopher T. Ritchlin1, Arthur Kavanaugh2, Joseph F. Merola3, Georg Schett4, Jose U. Scher5, Richard B. Warren6, Deepak Assudani7, Thomas Kumke8, Barbara Ink7 and Iain B. McInnes9, 1University of Rochester Medical Centre, Rochester, NY, 2UC San Diego School of Medicine, La Jolla, CA, 3Brigham and Women's Hospital Harvard Medical School, Boston, MA, 4Friedrich Alexander University Erlangen-Nurnberg, Erlangen, Germany, 5Department of Medicine, NYU Langone Medical Center, New York, NY, 6The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom, 7UCB Pharma, Slough, United Kingdom, 8UCB Pharma, Monheim am Rhein, Germany, 9University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: IL-17F shares structural homology and overlapping biologic function with IL-17A. In vitro studies demonstrate that IL-17F has biologic effector function that can modulate inflammation.…
  • Abstract Number: 2562 • 2018 ACR/ARHP Annual Meeting

    Secukinumab Improves Grappa-Omeract Core Domains of Psoriatic Arthritis

    Ana-Maria Orbai1, Iain B. McInnes2, Laura C. Coates3, M. Elaine Husni4, Dafna D Gladman5, Laure Gossec6, Luminita Pricop7, Olivier Chambenoit8, Xiangyi Meng8 and Philip J. Mease9, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Glasgow, Glasgow, United Kingdom, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4Cleveland Clinic, Cleveland, OH, 5Toronto Western Research Institute and University of Toronto, Toronto, ON, Canada, 6Université Pierre et Marie Curie and Hôpital Pitié-Salpêtrière, Paris, France, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, 8Novartis Pharmaceuticals Corporation, East Hanover, NJ, 9Swedish Medical Center and University of Washington, Seattle, WA

    Background/Purpose: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has demonstrated efficacy for patients with psoriatic arthritis (PsA) in multiple phase 3 clinical…
  • Abstract Number: 2563 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety of a Potent and Highly Selective Oral Tyrosine Kinase 2 Inhibitor, BMS-986165, in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase II, Randomized, Placebo-Controlled Trial

    Kim A Papp1, Kenneth B. Gordon2, Diamant Thaçi3, Akimichi Morita4, Melinda Gooderham5, Peter Foley6,7,8, Ihab G. Girgis9, Sudeep Kundu9 and Subhashis Banerjee9, 1Clinical Research and Probity Medical Research, Waterloo, ON, Canada, 2Medical College of Wisconsin, Milwaukee, WI, 3University of Luebeck, Luebeck, Germany, 4Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, 5SKiN Centre for Dermatology, Queen’s University and Probity Medical Research, Peterborough, ON, Canada, 6The University of Melbourne, Melbourne, Australia, 7St Vincent’s Hospital Melbourne & Probity Medical Research, Melbourne, Australia, 8Skin & Cancer Foundation Inc, Melbourne, Australia, 9Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: BMS-986165, a potent and highly selective oral tyrosine kinase 2 inhibitor, inhibits signal transducer and activator of transcription (STAT)-dependent signalling pathways of interleukin-23 and…
  • Abstract Number: 2572 • 2018 ACR/ARHP Annual Meeting

    Predictors for Use of Secukinumab 300mg over 150mg in Psoriatic Arthritis: A Meta-Analysis of Four Phase 3 Trials By Machine Learning

    Luminita Pricop1, Corine Gaillez2, Gregory Ligozio3, Xuan Zhu3 and David James3, 1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, 2Novartis Pharma AG, Basel, Switzerland, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ

    Background/Purpose: Subcutaneous secukinumab 150mg and 300mg are approved doses for the treatment of psoriatic arthritis (PsA) with the higher dose recommended for patients with anti-TNF inadequate…
  • Abstract Number: 142 • 2018 ACR/ARHP Annual Meeting

    Peripheral CD4+CD25+Foxp3+T Regulatory Cells Absolutely Reduce in Patients with Systemic Lupus Erythematosus

    Xiao-Qing Liu1, Na-Lin Lai2, Yanan Duan1, Junwei Chen1, Xiao-Feng Li3 and Chong Gao4, 1The Second Hospital of Shanxi Medical University, Taiyuan, China, 2Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, 3Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China, 4Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA

    Background/Purpose: Regulatory T (Treg) cells, with the capacity to suppress immune responses, and effector T (Teff) cells, to promote inflammation, have been intensively studied in…
  • Abstract Number: 2577 • 2018 ACR/ARHP Annual Meeting

    Long-Term Effect of Ixekizumab on Patient-Reported Outcomes in Patients with Psa and Inadequate Response to TNF Inhibitors: 2-Year Follow-up from a Phase 3 Study

    Anthony Turkiewicz1, Amanda M. Gellett2, Lisa Kerr2, Julie Birt2 and Jordi Gratacos3, 1Rheumatology Associates, Birmingham, AL, 2Eli Lilly and Company, Indianapolis, IN, 3Rheumatology, Hospital Parc Taulí, Sabadell - Barcelona, Spain

    Background/Purpose: PsA is a chronic and complex inflammatory disease with both articular and extra-articular symptoms, including joint pain, enthesitis, dactylitis, fatigue, and skin and nail…
  • Abstract Number: 238 • 2018 ACR/ARHP Annual Meeting

    IL Inhibitors Therapy in Rheumatic Diseases and the Risk of Malignancies: Systematic Review and Meta-Analysis of Rare Harmful Effects in Randomized Controlled Trials

    Jawad Bilal1, Irbaz Bin Riaz2, Adam Berlinberg3, Abdullah Alhifany4, Gilbert Ortega5 and Warda Faridi6, 1University of Arizona, Tucson, AZ, 2Mayo Clinic, Richestor, MN, 3Department of Internal Medicine, University of Arizona, Tucson, AZ, 4Department of Pharmacy, University of Arizona, Tucson, AZ, 5Internal Medicine, University of Arizona, Tucson, Tucson, AZ, 6Department of Hematology/Oncology, University of Arizona, Tucson, AZ

    Background/Purpose: Tumor necrosis factor alpha (TNFα) inhibitor therapy in patients with rheumatologic disorders is well known to increase the risk of malignancy. While the individual…
  • Abstract Number: 2582 • 2018 ACR/ARHP Annual Meeting

    Post-Marketing Safety of Secukinumab in Adult Patients with Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Cumulative Analysis across >96,000 Patient-Treatment Years Exposure

    Atul A. Deodhar1, Dafna D Gladman2, Iain B. McInnes3, Filip van Den Bosch4, Abhijit Shete5, Ruquan You6, Samina Hussain7 and Jorge Safi8, 1Oregon Health & Science University, Portland, OR, 2Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 4Rheumatology, Ghent University Hospital and VIB Ghent University, Gent, Belgium, 5Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, 6Shanghai Novartis Trading Limited, Shanghai, China, 7Novartis Healthcare Private Limited, Hyderabad, India, 8Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ

    Background/Purpose: Secukinumab, a fully human monoclonal IgG1 antibody that selectively neutralizes IL-17A, is currently approved in >75 countries for use in psoriasis /psoriatic arthritis and…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology